A GROUP OF PHARMACEUTICAL industry executives, academics and representatives from NGOs and the World Bank gathered at a symposium in February to discuss the implications of re-pricing medicines. The symposium, sponsored by the Journal of International Economic Law, addressed the effect of re-pricing on foreign policy, patents, international trade, and the pharmaceutical industry.

Among those putting the practice of re-pricing under the microscope were Osagie Imasogie, former vice president and director of GlaxoSmithKline Ventures, and Penn Law professors Jacques deLisle, Eric A. Feldman, and R. Polk Wagner. Other speakers included Juan Rovira, senior economist (pharmaceuticals) of the World Bank, and Edward T. Swaine, a professor at the Wharton School.